stockportfolio.pro
Stocks / CBIO vs MCTA
CBIO vs MCTA
Crescent Biopharma, Inc. and Charming Medical Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Crescent Biopharma, Inc. (CBIO) | Charming Medical Limited (MCTA) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $10.84M | $6.22M |
| Net income (latest FY) | $-153.94M | $1.20M |
| Revenue growth (5y CAGR) | 1.3% | 32.7% |
| Net margin | -1419.6% | 19.3% |
| Return on equity | -75.8% | 2435.0% |
| P/E ratio | — | 419.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CBIO — free Open MCTA — freeFrequently asked questions
Which is bigger, CBIO or MCTA?
Crescent Biopharma, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CBIO or MCTA?
Over the last five fiscal years, Charming Medical Limited grew revenue faster — 32.7%/yr versus 1.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.